Clinical trials: Acquired Immunodeficiency Syndrome
HIV Infections
Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
The purpose of this study is to evaluate the safety of and immune response to an experimental DNA HIV vaccine followed by boosting with an experimental modified vaccinia HIV vaccine (MVA) in HIV uninfected adults.
- Trial name
- NCT00574600
- Testing
- SAAVI DNA-C2 vaccine, SAAVI MVA-C vaccine
- Where
- 4 sites in United States, South Africa
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Psychoactive Substance Use, Mood Disorders
PrEP and Consumptions
HIV pre-exposure prophylaxis (PrEP) with Truvada®, a combination of two antiretrovirals (tenofovir \& emtricitabine) is a prevention strategy for HIV-negative people at high risk of acquiring HIV.
- Trial name
- PrEP (NCT03449771)
- Testing
- self-administered questionnaire
- Where
- 5 sites in France
- Volunteers
- 237 people
- Sponsor
- University Hospital, Montpellier
Opioid Use Disorder, HIV Infections
Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington
The investigators will implement a non-randomized observational clinical trial that will include a pop-up clinic for women who inject drugs (WWID) near venues for exchange sex and drug use in north Seattle.
- Conditions
- Opioid Use Disorder, HIV Infections, Chlamydia, Gonorrhea
- Trial name
- NCT06187064
- Testing
- Mobile Van Clinic
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Washington
Diabetic Retinopathy, HIV
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01591902
- Testing
- Tesamorelin
- Where
- 24 sites in United States
- Volunteers
- 129 people
- Sponsor
- Theratechnologies
HIV Infections
Quality of Life, Depression and Sexual Function in Men Living With HIV
This observational case-control study evaluates quality of life, depressive symptoms, and sexual function in heterosexual men living with HIV who are receiving effective combination antiretroviral therapy and have achieved…
- Trial name
- NCT07376239
- Where
- Turkey (Türkiye)
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Kocaeli University
HIV Infections
Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug that belongs to a new class of drugs, called C-C chemokine receptor type 5 (CCR5) receptor blockers.
- Trial name
- VICTOR-E1 (NCT00243230)
- Testing
- Vicriviroc 30 mg, Vicriviroc 20 mg, Background ART Regimen
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)
The purpose of this study is to determine whether it is better to start an anti-HIV regimen containing a protease inhibitor (PI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a PI in combination with an NNRTI.
- Trial name
- NCT00000922
- Testing
- Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate
- Where
- 17 sites in United States
- Volunteers
- 1,710 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Anal Squamous Intraepithelial Neoplasia
Seville Cohort of People Living With HIV at Risk for Anal Cancer
There is increasing awareness of augmenting risk of anal cancer in people living with HIV, especially among men who have sex with men (MSM).
- Trial name
- SeVIHanal (NCT03713229)
- Testing
- Screening for anal squamous intraepithelial lesions
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospitales Universitarios Virgen del Rocío
HIV/AIDS
PrEP My Way: A Novel PrEP Delivery System to Meet the Needs of Young African Women
The investigators will first develop, tailor, and refine PrEP My Way for use with young women in Kisumu, Kenya (Aim 1). The design firm will use a client-centered, iterative approach, involving up to 15 individual interviews and…
- Trial name
- NCT04408729
- Testing
- PrEP My Way
- Where
- Kenya
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)
This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13™ in pneumococcal vaccine-naïve adults infected with HIV and to 2) describe the safety, tolerability, and immunogenicity of…
- Trial name
- PNEU-WAY (NCT03480802)
- Testing
- V114, Prevnar 13™, PNEUMOVAX™23
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 302 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV/AIDS
Changing Health Through Food Support (CHEFS) Program
UCSF and Project Open Hand (POH), a community based organization in San Francisco which provides meals and groceries to chronically ill clients in the Bay Area, have partnered to conduct an initial randomized controlled trial…
- Trial name
- CHEFS (NCT03191253)
- Testing
- Medically-appropriate meals and groceries
- Volunteers
- 191 people
- Sponsor
- University of California, San Francisco
Stimulant Use, Human Immunodeficiency Virus (HIV)
Project neuroARTEMIS
The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave.
- Conditions
- Stimulant Use, Human Immunodeficiency Virus (HIV), Depression
- Trial name
- NCT06814275
- Testing
- ARTEMIS, Contingency management for Antiretroviral (ARV) adherence
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- Wake Forest University Health Sciences
HIV-1 Infection
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
During the course of HIV infection the number of CD4 cells decreases, resulting in a reduced immunological response and ultimately immune deficiency.
- Trial name
- IMID (NCT01704781)
- Testing
- Lenalidomide, Vacc-4X, rhuGM-CSF
- Where
- 4 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Bionor Immuno AS
HIV Infections
A Phase I Study of Methotrexate for HIV Infection
To determine the safety and tolerance of methotrexate in HIV-infected patients. To determine the dose effective in modulating key markers of immune activation.
- Trial name
- NCT00000834
- Testing
- Lamivudine, Methotrexate, Zidovudine
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Evaluation of Use of Clinical Decision Support System in HIV Care in Resource Constrained Settings
The purpose of this study is to determine whether the use of a Computerized Decision Support System (CDSS) in form of alerts to clinicians enhances early detection of immunological treatment failure in HIV patients.
- Trial name
- CDSS (NCT01634802)
- Testing
- EMR Only, EMR+CDSS
- Where
- Kenya
- Volunteers
- 1,460 people
- Sponsor
- Kenya Medical Research Institute
HIV Infections
A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
To determine the safety and immunogenicity of 200 mcg MN rgp160 vaccine (Immuno-AG) versus placebo, administered on two immunization schedules to healthy volunteers.
- Trial name
- NCT00001037
- Testing
- gp160 Vaccine (Immuno-AG)
- Where
- 2 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
PENTA15: Pharmacokinetic Study of Once Versus Twice Daily Abacavir in HIV-1 Infected Children Aged 3 to <36 Months
To compare the plasma pharmacokinetic (PK) parameters of q24h versus q12h dosing of abacavir in HIV-1-infected infants and children aged 3 months to 36 months The secondary objectives of PENTA15 were: To compare the plasma PK…
- Trial name
- PENTA15 (NCT01973439)
- Testing
- Intervention 1: PK assessment while on Twice Daily Abacavir, Intervention 2: PK assessment while on Once Daily Abacavir
- Where
- 10 sites in France, Germany and 3 more
- Volunteers
- 23 people
- Sponsor
- PENTA Foundation
HIV, Malaria
Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance
At least three studies in sub-Saharan Africa have demonstrated a decrease in morbidity or mortality among HIV-infected adults who took daily cotrimoxazole (trimethoprim sulfamethoxazole) [CTX] prophylaxis.
- Conditions
- HIV, Malaria, Diarrhea, Pneumonia
- Trial name
- NCT00137657
- Testing
- Cotrimoxazole (trimethoprim sulfamethoxazole)
- Where
- Kenya
- Volunteers
- 1,478 people
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections
Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults
Primary purpose of this study is to compare the efficacy and safety of two different nevirapine (Viramune) dosing regimens (once daily (QD) and twice daily (BID) application) and of atazanavir/ritonavir (Reyataz/Norvir), all on…
- Trial name
- NCT00389207
- Testing
- nevirapine bid, nevirapine qd, atazanavir
- Where
- 68 sites in Argentina, Germany and 8 more
- Volunteers
- 576 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, Malaria
Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Lopinavir/Ritonavir in HIV-infected Adults
Despite the clinical significance of potential interactions between antimalarials and antiretrovirals, no drug interaction studies have been published and there is an urgent need to address this gap in current knowledge.
- Trial name
- SEACAT 2_4_2 (NCT00869700)
- Testing
- Artemether/Lumefantrine
- Where
- South Africa
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Cape Town
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.